Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: A Systematic Review
Vittoria Perrotti1, Vito Carlo Alberto Caponio2, Marco Mascitti3
1Department of Medical, Oral and Biotechnological Sciences, Gabriele d'Annunzio University of Chieti-Pescara, 66100 Chieti, Italy.
Background:
Antibody-drug conjugates (ADCs) are designed to deliver potent cytotoxic agents into tumor tissues. During the last two decades, a plethora of ADCs have been successfully developed and used for several indications, including hematologic and solid tumors. In this work, we systematically reviewed the progress in ADC development for the treatment of HNC.
Methods:
This review was registered in PROSPERO database. A comprehensive search was conducted following PRISMA guidelines and using PubMed, Scopus and Web of Science database.
Results:
In total, 19 studies were included. Due to the significant heterogeneity of the outcome measures, meta-analysis was not performed, and data were summarized in tables. HNC results are poorly represented in the cohorts of completed clinical trials; published data are mostly focused on safety evaluation rather than efficacy of ADCs.
Conclusions:
Although several novel agents against a wide range of different antigens were investigated, showing promising results at a preclinical level, most of the targets reported in this review are not specific for HNC; hence, the development of ADCs tailored for the HNC phenotype could open up new therapeutic perspectives. Moreover, the results from the present systematic review call attention to how limited is the application of current clinical trials in HNC.
Insights
Antibody-drug conjugates (ADCs) show promise for head and neck cancer (HNC) treatment. However, current clinical trials have limited data on ADC efficacy in HNC, necessitating targeted ADC development.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Antibody-drug conjugates (ADCs) are engineered therapeutics delivering cytotoxic agents to tumors.
- ADCs have demonstrated success in treating various hematologic and solid tumors over the past two decades.
- This review systematically examines the advancements in ADC development specifically for head and neck cancer (HNC) treatment.
Purpose of the Study:
- To systematically review the progress of antibody-drug conjugate (ADC) development for head and neck cancer (HNC).
- To identify current trends and limitations in ADC research and clinical application for HNC.
Main Methods:
- Systematic literature search conducted adhering to PRISMA guidelines.
- Databases searched included PubMed, Scopus, and Web of Science.
- The review was registered in the PROSPERO database.
Main Results:
- Nineteen studies were included in the systematic review.
- Significant heterogeneity in outcome measures precluded meta-analysis; data were summarized.
- Published data on ADCs in HNC primarily focus on safety rather than efficacy, with limited representation in clinical trials.
Conclusions:
- Preclinical studies show promise for novel ADCs targeting various antigens.
- Most investigated targets are not specific to HNC, highlighting the need for HNC-tailored ADCs.
- Current clinical trials have limited application and data for HNC, underscoring the need for further research and development.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy